ClinicalTrials.gg
WithdrawnNCT01440231ADDRESSUpdated Aug 21, 2013

Atacicept Demonstrating Dose RESponSe

A Phase 2 interventional study of Placebo and Atacicept in Systemic Lupus Erythematosus, sponsored by EMD Serono. Withdrawn. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2013-08-21.

Sponsored by EMD Serono (part of Merck KGaA, Darmstadt, Germany) · Phase 2, Interventional, and Treatment

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
0
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-19

Among 12 studies in Lupus Erythematosus, Systemic by Merck KGaA, Darmstadt, Germany — 3 open to participants now, 4 under way, 3 of them phase 3. Lupus Erythematosus, Systemic · Merck KGaA, Darmstadt, Germany.

Enrollment
12th of 12
0 · median 280
Started
2012
the only one that year
Phase 2
6 of 12
none open now
Registered
2nd of 12
by date

Among the 12 studies in Lupus Erythematosus, Systemic by Merck KGaA, Darmstadt, Germany, this one is the 12th largest by enrollment, is the only one that started in 2012, is one of 6 in phase 2, and was the 2nd registered.

Lupus Erythematosus, Systemic

1,211 studies on the registry are indexed under Lupus Erythematosus, Systemic; 406 are open to participants now.

Browse Lupus Erythematosus, Systemic studies →

Open to participants now

3 of the 12 studies in Lupus Erythematosus, Systemic by Merck KGaA, Darmstadt, Germany are open now, in 12 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 3 open studies →

Who these studies take

Of the 284 Lupus Erythematosus, Systemic studies recruiting now, 94 (33%) set no upper age limit and 160 (56%) stop at 75 or younger; 54 take children under 18; 32 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 12 studies in Lupus Erythematosus, Systemic by Merck KGaA, Darmstadt, Germany, or all of them as a file.
02

Study summary

Systemic lupus erythematosis (SLE) is an autoimmune disease, meaning that the body's immune system attacks its own organs and tissues. Within the immune system, B-cells and plasma cells make proteins called antibodies, which in autoimmune disease can bind to one's own tissues and are thus referred to as autoantibodies. Atacicept blocks 2 factors in the body, called BLyS and APRIL, which are important for the maintenance of B-cells and plasma cells, and thus the production of antibodies. This study will assess whether treatment with atacicept can reduce SLE disease activity. Atacicept is still an experimental drug, meaning that it is not available outside of a clinical trial, and that its potential benefits and risks have not been fully determined.

A total of 175 subjects are planned to be randomized (35 subjects per treatment arm) in a 1:1:1:1:1 ratio to receive either atacicept 5 mg, atacicept 25 mg, atacicept 75 mg, atacicept 115 mg or matching placebo, given subcutaneously once weekly for 24 weeks.

The primary objective of the trial is to evaluate the efficacy of atacicept compared to placebo in reducing SLE disease activity in subjects treated with standard of care (SoC) therapy and to investigate the dose-response relationship.

The secondary objectives of the trial are:

  • To evaluate the effect of atacicept in reducing corticosteroid usage
  • To evaluate the safety and tolerability profile of atacicept in subjects with SLE
  • To confirm the PK and PD profiles of atacicept in SLE subjects
  • To evaluate the changes in the Medical Outcomes Study Short Form General Health Survey [SF-36].
03

Conditions studied

  • Systemic Lupus Erythematosus

Keywords

  • Rheumatology
  • Double-Blind
  • Placebo-Controlled
  • Multidose
  • Dose-Response
  • Phase II
  • Systemic Lupus Erythematosus
  • SLE
  • Atacicept
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Male or female of ≥18 years of age
  • Written
  • Diagnosis of SLE satisfying at least 4 out of the 11 ACR criteria during the course of their illness
  • Disease duration of at least 6 months
  • SLEDAI-2K score ≥ 6 at screening
  • Positive test results for antinuclear antibody (ANA) (HEp-2 ANA ≥1:80) and/or anti-double-stranded deoxyribonucleic acid (dsDNA) (≥30 IU/mL) at screening
  • Negative serum pregnancy test and highly effective method of for woman of .

Exclusion criteria

Exclusion Criteria:

  • Increase in dosing of within 2 weeks prior to screening
  • Introduction of MMF within 3 months prior to TD1 or increase in dosing within 1 month before screening
  • Change in dosing of or corticosteroids during the screening period
  • Serum IgG \< 6g/L
  • Estimated (GFR) \<50 mL/min/1.73m²
  • Urinary protein:creatinine ratio >2 mg/mg
  • History of demyelinating disease
  • Breastfeeding or pregnancy
  • Legal or limited legal capacity

Additional exclusion criteria also apply

Terms in these criteria, in plain language(6)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
0 participants (actual)

Study arms

  • Placebo comparator
    Arm 1

    Drug: Placebo

  • Experimental
    Arm 2

    Drug: Atacicept

  • Experimental
    Arm 3

    Drug: Atacicept

  • Experimental
    Arm 4

    Drug: Atacicept

  • Experimental
    Arm 5

    Drug: Atacicept

Interventions

06

What researchers measure

Primary outcomes

  1. Change from baseline (trial day 1) in SLEDAI-2K Responder Index-50 (SRI-50) at week 24 of therapy

    The SRI-50 is a modification of the SLEDAI-2K, and allows detection of partial improvements (at least 50%) in SLE signs and symptoms assessed by SLEDAI-2K (Systemic Lupus Erythamtosus Disease Activity Index- 2000).

    Time frame: 24 weeks

Secondary outcomes

  1. Change from baseline to Week 24 in corticosteroid dose

    Time frame: 24 weeks

  2. Change from baseline in serum Complement C3 levels at week 24 in subjects with low C3 at baseline

    Time frame: 24 weeks

  3. Change from baseline in serum Complement C4 levels at week 24 in subjects with low C4 at baseline

    Time frame: 24 weeks

  4. Change from baseline in anti-dsDNA antibodies (in subjects with anti dsDNA ≥30 IU/mL at baseline) and in ANA levels (in subjects with HEp-2 ANA ≥1:80 at baseline) at week 24

    Time frame: 24 weeks

  5. Change from baseline in levels of total Ig and Ig classes (IgG, IgA, and IgM) at week 24

    Time frame: 24 weekls

  6. The nature (preferred terms) and incidence of AEs

    Frequency tables summarizing the observed number of AEs by System Organ Class (SOC) and preferred term will be presented per regimen

    Time frame: 24 weeks

07

Study locations

No study locations are listed for this record.

08

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Feb 2012, a primary completion of Aug 2013 and a completion of Feb 2014. It does not say whether these dates are actual or estimated.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 22, 2011
First posted
Sep 26, 2011
Start
Feb 2012
Primary completionEst.
Aug 2013
CompletionEst.
Feb 2014
Last update
Aug 21, 2013
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 21, 2013, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT01440231
Lead sponsor
EMD Serono
Responsible party
Sponsor
First posted
Sep 26, 2011
Start date
Feb 2012
Primary completion
Aug 2013 (estimated)
Completion
Feb 2014 (estimated)
Last update
Aug 21, 2013

Study contacts

Stephen Wax, MD, PhD
study director · EMD Serono, Senior Medical Director, Rheumatology

Oversight

Data monitoring committee
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is withdrawn, as verified in Aug 2013. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: TACI receptor-IgG Fc fragment fusion protein

Start the discussion